flutamide

Flutamide (SCH 13521) is an antiandrogen with about the same potency as cyproterone in rodent and canine species.

Flutamide-D7 is intended for use as an internal standard for the quantification of flutamide by GC- or LC-MS. Flutamide (T0489) is an androgen receptor antagonist and prodrug form of 2-hydroxy flutamide. Flutamide (T0489) is converted to 2-hydroxy flutamide by the cytochrome P450 (CYP) isoform CYP1A2 in human liver microsomes. It is cytotoxic to PC3 and LNCaP prostate cancer cells with IC50 values of 98.8 and 81.8 µM, respectively. Flutamide (T0489) (50 mg/kg per day) reduces tumor growth in a PC-82 mouse xenograft model. Formulations containing flutamide have been used in the treatment of prostate cancer.

2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR) for the treatment of prostate cancer

PDDC inhibitor (Phenyl (R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl)carbamate) is a selective and highly potent nSMase2 inhibitor.

FlutaMide Related CoMpound B is used as pharmaceutical intermediates.